Welcome back to Plenary Session Podcast. We're at the intersection of medicine, oncology, and health policy. I'm back. I got a new episode for you. We got a lot to cover. The first part of this podcast I'm going to do maybe 30 minutes on randomized control trials 101. Basics, 2 to 1, 3 to 1 randomization. Why do we do randomized trials? When are they

suitable? What are there advantages over observational studies? A little bit about Kaplan Meyer

plots, a little bit about both blinding and concealment. And then in the second half of this

podcast, I go down to San Diego and I sit with Papaheim, Dr. Aaron Goodman, and he gives you his advice

on how he advises fellows on choosing the first job, finding it, negotiating it, choosing it.

All that will come in the second half.

If you like Planner Session podcast, leave us a written review on the iTunes store.

Tell us what you like about it and what you don't like about it.

You can follow the new blog post.

I'm going to be talking about that in the first part of this.

Developdrugs.substack.com.

And you should follow my YouTube channel because there are videos there that aren't always on the audio feed.

So stay tuned.

We got a lot in store for you,

and I'll be back with many, many more topics to come in the weeks to come.

So stay tuned.

Welcome back to the channel.

I want to talk about a new endeavor I have going.

It's called the Drug Development Letter.

It's a letter for people interested in cancer drug and other drug development,

particular cardiovascular and Alzheimer's drugs. It's at developdrugs.substack.com. And if you like

Plenary Session Podcast, if you like these sorts of critical appraisals of clinical trials,

...